Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Aurora

- PMLiVE

WHO reveals ‘extensive’ worldwide overuse of antibiotics during COVID-19 pandemic

Findings from the report reveal factors that could have contributed to the spread of antimicrobial resistance

Biogen Idec building

Biogen’s tocilizumab biosimilar Tofidence recommended by CHMP to treat arthritis and COVID-19

The committee’s decision was supported by evidence demonstrating Tofidence’s similarity to Roche’s RoActemra

- PMLiVE

FDA grants Invivyd’s Pemgarda emergency use authorisation for COVID-19 prevention

The long-acting monoclonal antibody is authorised for use in adults and adolescents

- PMLiVE

King’s College London and 11 London collaborate on health psychology

We’re delighted to announce that we are working in partnership with the Health Psychology department at King's College London. Professor Rona Moss-Morris is working with the agency on a shared...

11 London

- PMLiVE

Gilead shares positive real-world data for COVID-19 treatment Veklury in hospitalised patients

Results were presented at the Conference on Retroviruses and Opportunistic Infections

- PMLiVE

Cambridge study reveals potential biomarker and target for long COVID treatments

The pro-inflammatory molecule, IFN-Y, persisted until symptoms improved in patients

- PMLiVE

Study reveals T cells could provide more protection against Omicron in future vaccines

Memory T cells were found to be more effective at fighting SARS-CoV-2 than antibodies

Matt Hunt

How we’re making AI a part of life at 11 London

This article talks about how AI is being used more in advertising, showing how it can change the way things are done from planning out strategies to coming up with...

11 London

- PMLiVE

DNA-based vaccine induces strong antibody response against SARS-CoV-2

The DNA scaffold carries multiple copies of a viral antigen which mimics virus structures

- PMLiVE

Pfizer’s COVID-19 antiviral Paxlovid recommended by NICE for expanded use

The latest guidance will mean an estimated 5.3 million people will be eligible to access Paxlovid

- PMLiVE

Novavax’s updated COVID-19 vaccine granted Emergency Use Listing by WHO

Nuvaxovid XBB.1.5 is now approved for emergency use in all 194 WHO member states

- PMLiVE

Researchers improve understanding of COVID-19 virus and future variants

The study aims to contribute to the design of future COVID-19 vaccines and drugs

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links